Loading…
Reported covered position: Chief of Staff, Rep. Mike Ferguson; Deputy Chief of Staff, Rep. David McIntosh; Communications Director, House Government Reform and Oversight Subcommittee; Press Secretary, Rep. John Myers
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: BAXTER HEALTHCARE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues impacting medical device and technology manufacturers related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · fourth_quarter · RA
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
PWC US GROUP LLP via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Source: Senate LDA
| EQUITY MARKETS ASSOCIATION |
| 28 |
| 2020–2026 |
| DEPOSITORY TRUST CLEARING CORPORATION | 27 | 2020–2026 |
| Meta Platforms, Inc. | 27 | 2017–2022 |
| PUBLIC SERVICE ENTERPRISE GROUP INC | 25 | 2017–2022 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 24 | 2017–2022 |
| ALIBABA GROUP HOLDING LIMITED | 23 | 2016–2021 |
| C.R. BARD INC. | 19 | 2016–2020 |
| CARDINAL HEALTH, INC. | 18 | 2018–2022 |
| INTEGRA LIFESCIENCES CORP. | 18 | 2016–2020 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 17 | 2017–2020 |
| AT&T SERVICES, INC. | 16 | 2023–2026 |
| CELGENE CORPORATION | 16 | 2016–2019 |
| GILEAD SCIENCES, INC. | 16 | 2016–2019 |
| IOWNIT CAPITAL AND MARKETS, INC. | 16 | 2019–2022 |
| ONCOSEC MEDICAL INC. | 16 | 2018–2022 |
| BIOIDENTICAL HORMONE REPLACEMENT THERAPY COALITION | 15 | 2019–2022 |
| GAMIDA | 15 | 2020–2024 |
| FERRING PHARMACEUTICALS, INC. | 14 | 2023–2026 |
| HILL-ROM HOLDINGS | 14 | 2019–2022 |
| STRONGBRIDGE BIOPHARMA PLC | 11 | 2018–2020 |
| UROGEN PHARMA LTD. | 11 | 2020–2022 |
| BECTON, DICKINSON AND COMPANY | 10 | 2020–2022 |
| DCOR, LLC | 10 | 2019–2021 |
| GLOBAL AUTOMAKERS | 10 | 2017–2019 |
| THE CARLYLE GROUP | 10 | 2024–2026 |
| American Municipal Power, Inc. | 9 | 2017–2018 |
| CHARTER COMMUNICATIONS, INC. | 9 | 2017–2018 |
| CHILDREN'S HOSPITAL ASSOCIATION | 9 | 2017–2019 |
| EDGE THERAPEUTICS INC. | 9 | 2016–2018 |
| ADVAXIS, INC. | 8 | 2016–2017 |
| GAMECHANGE SOLAR | 8 | 2025–2026 |
| INTERNATIONAL MOTORS, LLC | 8 | 2025–2026 |
| JS LINK, INC. (FORMERLY DNA LINK CO., LTD.) | 8 | 2025–2026 |
| OPHTHOTECH CORP. | 8 | 2016–2017 |
| ORCHID GLOBAL, INC. | 8 | 2021–2023 |
| STRYKER CORPORATION | 8 | 2025–2026 |
| ARALEZ PHARMACEUTICALS US INC. | 7 | 2016–2017 |
| SOUTHERN RESEARCH | 7 | 2023–2025 |
| GENENTECH INC | 6 | 2016–2017 |
| HEARING INDUSTRIES ASSOCIATION | 6 | 2025–2026 |
| INSMED INCORPORATED | 6 | 2018–2019 |
| AMERICAN CHEMISTRY COUNCIL | 5 | 2017 |
| ARCHER DANIELS MIDLAND COMPANY | 5 | 2024–2025 |
| BAXTER HEALTHCARE CORPORATION | 5 | 2022 |
| Barnes & Noble Education, Inc. | 5 | 2020 |
| OSRX, INC. | 5 | 2025–2026 |
| PROSPECT MEDICAL HOLDINGS, INC. | 5 | 2017 |
| RIPPLE LABS, INC. | 5 | 2017–2018 |
| SEMPRA ENERGY | 5 | 2022 |
| TEXAS CHILDREN'S HOSPITAL | 5 | 2017 |
| THE FREEDOM INITIATIVE | 5 | 2022 |
| TYME TECHNOLOGIES, INC. | 5 | 2020 |
| AEROFLOW HEALTHCARE | 4 | 2017 |
| FINRA FINANCIAL INDUSTRY REGULATORY AUTHORITY | 4 | 2016–2017 |
| PRIME TIME COMMERCE, LLC | 4 | 2020 |
| Pentec Health, Inc. | 4 | 2017 |
| Portola Pharmaceuticals, Inc. | 4 | 2017 |
| SEKO LOGISTICS | 4 | 2024 |
| SQI DIAGNOSTICS | 4 | 2020–2021 |
| THE MEDICINES COMPANY | 4 | 2016 |
| TRIPLE FIVE WORLDWIDE | 4 | 2020 |
| WEBER-STEPHEN PRODUCTS LLC | 4 | 2020–2021 |
| DEPOMED INC | 3 | 2017 |
| ENGAGE CUBA | 3 | 2017 |
| VENTURE QUEST CAPITAL PARTNERS | 3 | 2020 |
| YAMO PHARMACEUTICALS, LLC | 3 | 2018 |
| LINCOLN FINANCIAL GROUP | 2 | 2017 |
| CALIFORNIA WALNUT COMMISSION | 1 | 2022 |
| GOLDEN STATE NATURAL RESOURCES, INC. | 1 | 2021 |
| GOLDEN VALLEY ELECTRIC ASSOCIATION | 1 | 2022 |
| IRANIAN AMERICAN COMMUNITY OF NORTHERN CALIFORNIA | 1 | 2022 |
| NATIONAL HEALTHY START ASSOCIATION | 1 | 2022 |
| STRATEGIES 360 |
| 1 |
| 2022 |
| TOWNSEND PUBLIC AFFAIRS, INC | 1 | 2021 |
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: BAXTER HEALTHCARE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues impacting medical device and technology manufacturers related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Contact Lens Prescription Verification Modernization Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Further Consolidated Appropriations Act, 2020
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2207, the Protect Medical Innovation Act. S. 692, the Protect Medical Innovation Act.
Further Consolidated Appropriations Act, 2020
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Further Consolidated Appropriations Act, 2020
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S.692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Further Consolidated Appropriations Act, 2020
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S.692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.69, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.69, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2207, the Protect Medical Innovation Act. S. 692, the Protect Medical Innovation Act.
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Contact Lens Prescription Verification Modernization Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Clean Water Through Green Infrastructure Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Clean Water Through Green Infrastructure Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Prescription Drug Pricing Reduction Act of 2019
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Policy issues related to financial services, accounting and auditing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · 3T
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
JS LINK, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MOTORS, LLC via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policy issues related to tariffs and domestic manufacturing.
Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GAMECHANGE SOLAR via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
DEPOSITORY TRUST & CLEARING CORPORATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policy issues related to capital markets and the clearance and settlement of securities transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
THE CARLYLE GROUP via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
PWC US GROUP LLP via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues related to financial services, accounting and auditing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
JS LINK, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MOTORS, LLC via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.
Policy issues related to tariffs and domestic manufacturing.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GAMECHANGE SOLAR via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
DEPOSITORY TRUST & CLEARING CORPORATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues related to capital markets and the clearance and settlement of securities transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
THE CARLYLE GROUP via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
PWC US GROUP LLP via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to financial services, accounting and auditing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
JS LINK, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MOTORS, LLC via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.
Policy issues related to tariffs and domestic manufacturing.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
GAMECHANGE SOLAR via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
DEPOSITORY TRUST & CLEARING CORPORATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to capital markets and the clearance and settlement of securities transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
THE CARLYLE GROUP via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PWC US GROUP LLP via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to financial services, accounting and auditing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
DEPOSITORY TRUST & CLEARING CORPORATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to capital markets and the clearance and settlement of securities transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Multiple tax policies, including provisions of Public Law No. 115-97 and Public Law No. 119-21.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
JS LINK, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MOTORS, LLC via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to tariffs and domestic manufacturing.
Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GAMECHANGE SOLAR via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
THE CARLYLE GROUP via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · RR
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · 3A
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
PWC US GROUP LLP via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues related to financial services, accounting and auditing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
NASDAQ, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL MOTORS, LLC via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.
Policy issues related to tariffs and domestic manufacturing.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
JS LINK, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GAMECHANGE SOLAR via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
DEPOSITORY TRUST & CLEARING CORPORATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues related to capital markets and the clearance and settlement of securities transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
THE CARLYLE GROUP via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Multiple tax policies, including provisions of Public Law No. 115-97 and Public Law No. 119-21.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · RR
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
PWC US GROUP LLP via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues related to financial services, accounting and auditing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
INTERNATIONAL MOTORS, LLC via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.
Policy issues related to tariffs and domestic manufacturing.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
GAMECHANGE SOLAR via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Tax provisions that promote domestic manufacturing, including sections of Public Law No. 117-169.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
DEPOSITORY TRUST & CLEARING CORPORATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues related to capital markets and the clearance and settlement of securities transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
JS LINK, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CARLYLE GROUP via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Multiple corporate tax provisions, including those in Public Law No. 115-97, the Tax Cuts and Jobs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Multiple corporate tax provisions, including those in Public Law No. 115-97, the Tax Cuts and Jobs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Multiple tax policies, including provisions of the Tax Cuts and Jobs Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SOUTHERN RESEARCH via BAKER & HOSTETLER LLP
2025 · first_quarter · 1T
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PWC US GROUP LLP via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues related to financial services, accounting and auditing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
INTERNATIONAL MOTORS, LLC via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues related to tariffs and domestic manufacturing.
Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE